Table 1.
Clinical characteristics and CD56 expression status of 443 patients at diagnosis with NKTCL.
| Characteristics | All cases (n=443,100%) | CD56-positive Group (n=337, 76.1%) | CD56-negative Group (n=106, 23.9%) | P value |
|---|---|---|---|---|
| Gender | 0.230 | |||
| Male | 299 (67.5%) | 233 (69.1%) | 66 (62.3%) | |
| Female | 144 (32.5%) | 104 (30.9%) | 40 (37.7%) | |
| Age at diagnosis >60 (years) | 64 (14.4%) | 44 (13.1%) | 20 (18.9%) | 0.185 |
| ECOG PS score ≥2 | 94 (21.2%) | 61 (18.1%) | 33 (31.1%) | 0.006* |
| Subtypes | 0.974 | |||
| Nasal cavity | 309 (69.8%) | 236 (70.0%) | 73 (68.9%) | |
| Extranasal UAT | 93 (21.0%) | 70 (20.8%) | 23 (21.7%) | |
| Extra UAT | 41 (9.2%) | 31 (9.2%) | 10 (9.4%) | |
| B-symptoms | 205 (46.3%) | 148 (43.9%) | 57 (53.8%) | 0.096 |
| Primary tumor invasion | 268 (60.5%) | 198 (58.8%) | 70 (66.0%) | 0.221 |
| Extranodal sites ≥ 2 | 87 (19.6%) | 67 (19.9%) | 20 (18.9%) | 0.929 |
| Regional lymphadenopathy | 191 (43.1%) | 143 (42.4%) | 48 (45.3%) | 0.686 |
| Elevated serum LDH level | 120 (27.1%) | 92 (27.3%) | 28 (26.4%) | 0.957 |
| Ann Arbor Stage | 0.886 | |||
| I, II | 389 (87.8%) | 295 (87.5%) | 94 (88.7%) | |
| III, IV | 54 (12.2%) | 42 (12.5%) | 12 (11.3%) | |
| IPI score | 0.047* | |||
| 0, 1 | 335 (75.6%) | 263 (78.0%) | 72 (67.9%) | |
| ≥ 2 | 108 (24.4%) | 74 (22.0%) | 34 (32.1%) | |
| KPI score | 0.318 | |||
| 0, 1 | 267 (60.5%) | 208 (61.7%) | 59 (55.7%) | |
| ≥ 2 | 176 (39.5%) | 129 (38.3%) | 47 (44.3%) |
ECOG PS, Eastern Cooperative Oncology Group performance status; Extranasal UAT, Extranasal upper aerodigestive tract; Extra UAT, extraupper aerodigestive tract; LDH, lactate dehydrogenase; IPI, International Prognostic Index; KPI, Korean Prognostic Index.
*Indicates statistically significant.